Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. scholar.google.com › citations‪John F Seymour‬ - ‪Google Scholar‬

    Articles 1–20. ‪Professor of Medicine, Director Dept of Haematology Peter MacCallum Cancer Centre & Royal Melbourne‬ - ‪‪Cited by 66,845‬‬ - ‪Hematologic malignancies‬.

  2. Imágenes

    • John Seymour | Congress.gov | Library of Congress
    • World's Top Medicine Scientists: H-Index Medicine Science Ranking in ...
    • [Police Chief John F. Seymour] — Calisphere
    • Photos de John Seymour - Babelio.com
    • John Seymour (author) - Alchetron, The Free Social Encyclopedia

    Ver todo

  3. www.nejm.org › doi › fullVenetoclax–Rituximab in Relapsed or Refractory Chronic...

    21 de mar. de 2018 · Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 2016;127:3215-3224.

  4. ashpublications.org › blood › articleDegraders upgraded: the rise of PROTACs in hematological...

    28 de mar. de 2024 · Casan and Seymour provide a state-of-the-art review of proteolysis-targeting chimeras (PROTACs), the leading class of targeted protein degradation agents.

  5. ashpublications.org › blood › articleAbstract - American Society of Hematology

    5 de nov. de 2021 · Abstract. Background: The phase 3 head-to-head trial of acalabrutinib (acala) vs ibrutinib (ibr) (NCT02477696) demonstrated noninferior efficacy and improved tolerability with acala in previously treated CLL (Byrd J Clin Oncol 2021).

  6. en.wikipedia.org › wiki › John_Seymour_(California_politician)John Seymour (California politician) - Wikipedia

    John Francis Seymour Jr. (born December 3, 1937) is an American retired politician who served as a United States senator from California from 1991 to 1992.

  7. www.onclive.com › authors › john-f-seymour-mbbs-phdJohn F. Seymour, MBBS, PhD - OncLive

    12 de dic. de 2018 · John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer...

  8. ashpublications.org › blood › articleFirst Results from a Phase 1, First-in-Human Study of the...

    2 de nov. de 2023 · Key secondary objectives are to assess pharmacokinetics, pharmacodynamics (PD), and preliminary antitumor activity. Safety was assessed according to CTCAE v5.0 (all pts) and iwCLL hematologic toxicity criteria (pts with CLL). Dose-limiting toxicities (DLTs) were assessed in the first 4 weeks.